Asset Details
Do you wish to reserve the book?
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
Do you wish to request the book?
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
2016
Overview
Summary
Background
Cabozantinib and gemcitabine improve tumor control in pancreatic ductal adenocarcinoma (PDAC) in preclinical models through c-Met inhibition. We sought to determine the maximum tolerated dose (MTD) of this combination in patients with advanced PDAC.
Methods
Patients with ≤1 prior treatment and adequate performance status were eligible. Cabozantinib was given orally once daily, beginning day (−)7 and continued with gemcitabine given intravenously on days 1, 8, and 15 every 28 days. Dose level was assigned using Time to Event Continual Reassessment Method (TITE-CRM). Primary endpoint was MTD, defined as the highest dose level at which ≤25 % of patients incurred a dose-limiting toxicity (DLT). Secondary endpoints included response rate, progression-free survival (PFS), overall survival (OS) and urinary biomarker assessment.
Results
Twelve patients were enrolled and treated with 10 patients evaluable for DLT. The probability of DLT was >25 % for all dose levels tested, and thus an MTD was not determined. DLTs included grade 3 ALT/AST elevations and thrombocytopenia. Three patients had partial responses, but each discontinued therapy due to toxicity. Median PFS and OS were 4.7 (95 % CI: 1.4–9.7) and 10.1 months (95 % CI: 3.6–20.6). Exploratory biomarker analysis showed correlation of c-Met and VEGF levels with response.
Conclusions
An MTD for the combination was not established. Cabozantinib and gemcitabine appear impractical for further development due to DLT at low doses and continuing toxicities with ongoing therapy. Acknowledging the small sample size, responses were seen suggesting further investigation of c-Met inhibition in PDAC may be warranted.
Publisher
Springer US,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Anilides - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biomarkers, Tumor - metabolism
/ Deoxycytidine - administration & dosage
/ Deoxycytidine - analogs & derivatives
/ Female
/ Humans
/ Kinases
/ Male
/ Medicine
/ Oncology
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - metabolism
/ Pancreatic Neoplasms - pathology
/ Patients
/ Pyridines - administration & dosage
/ Toxicity
/ Tumors
